Apimeds Pharmaceuticals adds two key executives to leadership team

NEW YORK - Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS), a clinical-stage biopharmaceutical company with a market capitalization of $21.3 million, has appointed two new executives to its leadership team, the company announced Tuesday. Trading at $1.77 per share, InvestingPro analysis indicates the company faces financial challenges, with short-term obligations exceeding liquid assets.

Susan Kramer, DrPH, joins as Senior Vice President of Development, while Brian Peters has been named Head of the company’s ai²™ division. Kramer will oversee all product development activities, including the company’s lead candidate Apitox, an intradermally administered bee venom-based therapeutic.

Kramer brings over 30 years of biopharmaceutical research experience, including 18 years at Genentech and most recently serving as Executive Vice President of Development at Concentric Analgesics. She holds a DrPH in Biomedical Sciences from the University of California, Berkeley.

Peters, who previously served as Chief Strategy & Insights Officer at Heller Agency and VP of Sales & Marketing at Medexus Pharma, will lead the strategy and positioning of the company’s proprietary ai²™ platform.

"Strengthening our operational leadership has been a priority since our IPO," said Erik Emerson, Chief Executive Officer of Apimeds, according to the company’s press release. According to InvestingPro data, the company is not yet profitable, with a weak financial health score. Get access to 3 more exclusive ProTips and comprehensive financial analysis with an InvestingPro subscription.

Apimeds is currently developing Apitox as a potential treatment for osteoarthritis knee pain in patients who don’t respond adequately to conservative therapy and common analgesics.

The company completed its initial public offering earlier this year and is working to advance its pipeline of bee venom-based therapeutics through clinical development. Investors should note that Apimeds’ next earnings report is scheduled for August 19, 2025, which could provide crucial updates on the company’s development progress.

In other recent news, Apimeds Pharmaceuticals US, Inc. announced the extension of maturity dates for three of its outstanding promissory notes. The original notes, issued to Inscobee Inc. and Apimeds Korea, were set to mature in 2025 and 2026. These amendments extend the maturity dates to May 19, 2026, while maintaining an interest rate of 5% per annum. This adjustment provides the company with increased financial flexibility. In another development, Apimeds Pharmaceuticals began trading on the New York Stock Exchange at $4 per share, consistent with its initial public offering (IPO) pricing. The IPO involved the sale of 3,375,000 shares, expected to generate gross proceeds of $13.5 million before deductions. The company also granted underwriters a 45-day option to purchase an additional 506,250 shares at the IPO price. D. Boral Capital LLC is serving as the sole book-running manager for this offering.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.